Finkarma

Unveiling the Power of Equity Trading. Join us on the path to Trading Excellence.

[Finkarma @finkarmaIN]

Follow FINKARMA NEWS UPDATES channel on Telegram for the latest news.

https://t.co/EYfIYeTLgi

[Finkarma @finkarmaIN]

📊 1. Impressive Q3 FY25 Performance:

-Revenue: ₹1,265 Cr (+24% YoY) 📈

-EBITDA: ₹670 Cr (+20% YoY), Margin: 52.9% 🚀

-Net Profit: ₹336 Cr (+32% YoY) 💰

-Cargo Volumes: 29.4 MT (+5% YoY); 3rd-party Cargo: 49% (Up from 39%) ✅

📅 2. Robust 9M FY25 Results:

-Revenue: ₹3,457 Cr (+22% YoY) 💹

-EBITDA: ₹1,885 Cr (+22% YoY) 📈

-Net Profit: ₹1,006 Cr (+21% YoY) 🔥

-Cargo Volumes: 85.7 MT (+11% YoY); 3rd-party Cargo soared 45% YoY 🚛

🎯 3. Clear Strategic Priorities:

✅ Expand port capacity from 174 mtpa to 400 mtpa by FY30

✅ Grow logistics segment to ₹8,000 Cr revenue with 25% EBITDA margin by FY30

✅ Actively seek strategic & value-accretive acquisitions 💼

🚧 4. Exciting Expansion Projects Underway:

Brownfield:

-Jaigarh & Dharamtar (+36 mtpa by FY27)

-Goa Port (+6.5 mtpa by FY25)

Greenfield:

-Keni Port (Karnataka, 30 mtpa by FY29)

-Jatadhar Port (Odisha, 30 mtpa by FY28)

Terminals:

-JNPA Liquid (4.5 mtpa by FY26)

-Tuticorin Bulk (7 mtpa by FY26)

🚛 5. Logistics Expansion - A Strategic Leap:

-Investing ₹9,000 Cr by FY30

-Acquired 70.37% in Navkar Corp for pan-India logistics

-Developing 15-20 terminals nationally

-Asset-light via Gati Shakti terminals for cost efficiency ⚡️

⚙️ 6. Specialized Infrastructure - Pipeline Project:

-302 km Slurry Pipeline (Odisha), 30 mtpa capacity ✅

-Operational by April 2027 supporting JSW Utkal Steel 🏭

💪 7. Solid Financial Health:

-Low net debt: ₹827 Cr

-Net debt-to-EBITDA at just 0.4x

-Strong cash reserves: ₹4,845 Cr, ensuring ample growth funding 💰

🌱 8. Sustainability Leadership (ESG):

-Rated "Low Risk" by Sustainalytics ✅

-Increasing renewable energy usage ♻️

-Commitment to reduce emissions & environmental footprint 🌍

🚀 9. Competitive Advantages:

-Rising 3rd-party cargo (now 49%) enhancing stability & profitability 📦

-Strategically located ports enabling seamless logistics & cost optimization 🌐

🗣️ 10. Management Optimism & Guidance:

-Confident on sustaining 10%+ annual cargo growth beyond FY25 📈

-Targeting higher EBITDA margins (58% ports, 25% logistics by FY30) 📊

🔮 📌 Bottom Line:

✅ Clear & aggressive expansion strategy
✅ Healthy financials & balance sheet
✅ Expanding high-margin third-party logistics
✅ Robust sector tailwinds from Govt. initiatives (Sagarmala, NIP)
✅ Solid execution track record & visionary leadership

JSW Infrastructure is exceptionally positioned for sustainable growth.Definitely a stock to watch! 🚢📈

📲 #JSWInfra #Ports #Logistics #Q3Results #InfraGrowth #StockMarket #StocksToWatch #IndiaGrowth

[Finkarma @finkarmaIN]

🚢 Detailed Analysis on JSW Infrastructure 🧵👇

by @FUNDAFORSTOCKS

[Finkarma @finkarmaIN]

🚀 Mega Thread: Indian CRDMOs – The Next Pharma Frontier 🇮🇳💊

By @FUNDAFORSTOCKS

🧵 1⃣ What are CRDMOs?

🔬 Contract Research, Development & Manufacturing Organizations

📌 Offer Pharma end-to-end services: Discovery→Development→Manufacturing

🚀 Help Pharma reduce costs, speed up timelines, manage risks, and deliver complex molecules

🌎 2⃣ Global CRDMO Market Snapshot

📊 Current Market: ~US$197 bn (2023)

🚀 Projected Growth: ~9% CAGR, reaching ~US$300 bn by 2028

🔥 Innovator-focused CRDMO (~US$140 bn) growing even faster

🎯 Outsourcing from Pharma jumped from <20% (2000s) to 42% today, heading towards ~47% by 2028

🔥 3⃣ Why CRDMOs Are Booming Globally

💰 Drug development costs skyrocketing (>US$1 bn per drug, up 10x since the 1970s)

⚠️ Declining R&D success rates (~11% today from ~25% earlier)

🚧 Rising complexity in drug discovery (Biologics, ADCs, Peptides)

🌐 Small & mid-sized Pharma increasingly dependent on specialized outsourcing

🇮🇳 4⃣ India's CRDMO Boom: Huge Opportunity

📌 Current Market Size: ~US$3 bn (2024)

🚀 Projected Size: ~US$12 bn by 2034 (14% CAGR)

🌏 Capturing ~30% incremental demand from global innovators shifting away from China (China+1)

✨ 5⃣ India's Key Competitive Advantages

💡 Cost-effective R&D (~60% cheaper) & Manufacturing (~75% cheaper) vs. US/EU

🎖️ Largest number of US FDA-approved Pharma plants after the US

🎓 Massive talent pool (~24k STEM PhDs annually)

🛡️ Strengthening IP regime and supportive Govt. policies (PLI schemes, Biotech clusters)

📌 6⃣ Major Growth Drivers in India

🌐 Global Pharma reducing dependency on China (current China market: ~US$28 bn)

🧬 Increased demand for specialized therapies (ADCs, HPAPIs, Peptides, Oligonucleotides)

🤝 Growing preference for integrated services (discovery through commercialization)

💉 Higher regulatory scrutiny pushing innovators to India (reliable quality standards)

🏅 7⃣ Top Indian CRDMOs

✅ Piramal Pharma
✅ Syngene International
✅ Sai Life Sciences

💠 8⃣ Piramal Pharma

🔹 Robust diversified capabilities: ADCs, HPAPIs, sterile injectables
🔹 Strong molecule pipeline: 150+ molecules, 14-15 launches expected by FY28

🔹 EBITDA margin expansion (~630 bps FY24–28E)

🔹 Significant Free Cash Flow generation (~₹17 bn FY25–28E), improved balance sheet

💎 9⃣ Syngene International

🔸 India's leading integrated CRDMO player (Discovery to Commercialization)

🔸 Strong Biologics and small molecule expertise, reliable regulatory compliance

🔸 Robust client base (400+ global innovators)

🔸 Integrated platform "SynVent" (~18-20 active projects) driving growth

🔸 Strong financial trajectory (14-19% CAGR: Sales, EBITDA, EPS FY24–28E)

♾ 🔟 Sai Life Sciences

▫️ Integrated discovery-to-manufacturing capabilities, strong molecule pipeline (170+)

▫️ Healthy growth (EBITDA ~29% CAGR FY24–28E)

🧬 1⃣1⃣ India's Advanced CRDMO Technological Capabilities

🌱 Flow Chemistry, Continuous Manufacturing, Recombinant DNA, Electrochemistry, Fermentation

⚗️ Complex therapeutics: Antibody-Drug Conjugates (ADCs), Peptides, Highly Potent APIs (HPAPIs), Biologics, Cell & Gene therapies

💡 Continuous investments strengthening global competitive positioning

🤖 1⃣2⃣ AI & Digitalization Transforming CRDMOs

🚀 AI & ML enabling faster molecule screening, precision targeting, quicker clinical trials

🧬 Complexity shifting towards biology/DMPK studies, away from traditional computational chemistry

⏳ Accelerating discovery timelines, improving overall efficiency, and driving down costs

🤝 1⃣3⃣ Evolution of Pharma-CRDMO Partnerships

🔄 Moving from simple vendor-client to strategic risk-sharing partnerships

🏦 Increased joint ventures, co-investments, and shared R&D responsibilities

📈 Growing demand for integrated end-to-end services reducing complexities, improving timelines & quality

⚡ 1⃣4⃣ Potential Risks & Challenges

🐢 Sluggish biotech funding recovery impacting small innovators

🗳️ Uncertainty regarding US Biosecure Act potentially slowing China+1 diversification

🏢 Rising competition from Pharma’s in-house Global Capability Centers (GCCs)

📌 Tariff-related risks indirectly affecting Indian competitiveness

🌟 1⃣5⃣ Competitive Benchmarking: India vs Global

🌐 Strong global competitiveness in small molecules & regulatory compliance

🔍 Gaps in biologics and presence in global innovation hubs (US/UK), ongoing efforts to bridge through talent acquisition & strategic partnerships

💡 Active capacity expansions and capability upgrades across Indian players

📈 1⃣6⃣ Long-Term CRDMO Outlook

🎯 Indian CRDMO market forecasted at US$12 bn by 2034 (~14% CAGR)

🌏 Multiple structural tailwinds: global outsourcing, innovation demand, China+1 shift, and supportive policies

🚀 Strategic investments in advanced capabilities securing sustained long-term growth

🎖️ 📌 Final Takeaways for Investors

🔑 Prioritize integrated CRDMOs with robust tech capabilities & solid pipeline

💡 Favor disciplined valuations, global client networks, and strong R&D capabilities

✅ CONCLUSION:
Indian CRDMOs stand at the cusp of multi-year explosive growth. Investors should strategically position themselves in companies with integrated service offerings, advanced technological capabilities, robust pipelines, and attractive valuations.

⚠️Not a BUY/SELL advice⚠️

Like 👍 & Repost 🔄 if you found this insightful!

📌 Follow @FUNDAFORSTOCKS , @finkarmaIN for more industry deep dives & actionable market insights!

#CRDMO #Pharma #India #Biotech #Investing #Stocks #MarketInsights

[Finkarma @finkarmaIN]

1️⃣ India’s Largest Airline – Overview

-Fleet size: 437 aircraft; plans for 600+ aircraft by FY2030.
-Passenger volume: Welcomed 113 million passengers in FY25.
-Daily flights: Operating over 2,200 flights/day, connecting 131 destinations (91 domestic, 40 international).

2️⃣ Strong Macro Tailwinds

-India set to become 5th largest economy globally.
-Domestic aviation passengers expected to double (510M by FY2030).
-High growth driven by rising incomes, Gen-Z travelers, and infrastructure expansion.

3️⃣ Untapped International Opportunity

-India’s international seats per capita remain low (0.06), huge room for growth.
-Expanding international seat share from ~28% in FY25 to ~40% by FY30.
-Adding wide-body aircraft (Airbus A350s & damp-leased Boeing 787s) and new Airbus A321 XLRs from FY26 for long-haul connectivity.

4️⃣ Cost Leadership and Efficiency

-One of the lowest operational costs globally among LCCs.
-Strong operational metrics:
On-Time Performance (84.4%),
Flight completion rate (99.5%),
High aircraft utilization rates.

-Extensive in-house maintenance & engineering capabilities to minimize downtime.

5️⃣ Robust Aircraft Order Book

-Secured deliveries of 925 aircraft until 2035.
-Recent landmark 500 aircraft Airbus order (largest ever single-airline order with Airbus).
-Diverse fleet: A320neo, A321neo, ATR turboprops, A350 widebodies, and damp-leased Boeing 787s.

6️⃣ Premium Offerings & Ancillary Revenue Growth

-Introduced "IndiGo Stretch" (Business Class) on selected routes, enhancing yields.
-Strong ancillary revenue growth projected: targeting a 30% increase per passenger from FY24-FY26.
-Successful loyalty program launch (BluChip): Over 2 million members enrolled in 5 months.

7️⃣ Digital Transformation & Customer Experience

-Redesigned website & mobile app: 82% YoY growth in website traffic, 33% increase in mobile adoption.
-Advanced tech initiatives: AI-enabled chatbot (6ESkai), automated baggage weighing (BagWatch), mobile breathalyzers (6E Digi Breathalyzer).
-Enhanced direct sales channels (up 55%), improving margins and customer engagement.

8️⃣ Expanding CarGo Operations

-Leveraging extensive domestic & international network for cargo.
-Cargo capacity enhancements via wide-body aircraft (10 tons per flight) & freighters (20+ tons).
-Positioned well to capture growth in logistics, e-commerce, and Make-in-India manufacturing exports.

9️⃣ Financial Strength & Profitability

-FY25 financial performance strong with total income reaching INR 795 billion (up 18% YoY).
-EBITDAR margins (ex-forex) of ~27%, showcasing consistent profitability.
-Net profit after tax: INR 61 billion for trailing 12 months (Dec’24).
-Robust cash reserves (INR 289 billion) provide ample financial flexibility.

🔟 ESG Commitment & Global Leadership

-Emissions: Targeting 23% reduction in GHG emissions by FY2030 vs. FY16 baseline.
-Fleet composed primarily of new-generation, fuel-efficient aircraft, ensuring minimal environmental footprint.
-Global leader in diversity: employing the highest number of female pilots worldwide.
-Strong CSR initiatives: Skill development, women empowerment, ecological sustainability (177k saplings planted), heritage conservation.

1️⃣1️⃣ Strategic Risk Management

-Effective mitigation strategies in place for fuel volatility, forex fluctuations, inflation, regulatory changes, and supply-chain disruptions.
-Proactively managing aircraft-on-ground (AOG) situations through secondary leases and damp leases, maintaining operational continuity.

1️⃣2️⃣ Recognition & Industry Accolades

-Awarded Airline of the Year 2024.
-Recognized for the Youngest Aircraft Fleet globally (2025).
-Achievements in cargo excellence, customer experience, diversity inclusion, and sustainability practices.

📈 Future Growth Outlook (FY2026+)

-Committed to continued double-digit capacity and passenger growth.
-Network expansion: Targeting 145+ destinations within the next year.
-Sustained investment of INR 300 crores into aviation innovation and tech-driven ventures.

🌐 Conclusion

IndiGo is strongly positioned for sustained market leadership, underpinned by strategic internationalization, disciplined financial
management, and industry-leading ESG practices.
#IndiGo #InvestorDay #IndianAviation #AviationNews #ESG #Sustainability #Growth #Stocks #India

[Finkarma @finkarmaIN]

🧵 A detailed breakdown of IndiGo’s ambitious growth roadmap, financial health, strategic plans from their latest investor presentation:
By @FUNDAFORSTOCKS

✈️ IndiGo Investor Presentation Highlights (March 2025)

[Finkarma @finkarmaIN]

Follow @finkarmaIN
Follow @FUNDAFORSTOCKS
✅Like
✅Follow
✅Repost

[Finkarma @finkarmaIN]

🧵 THREAD: Market FALL? Trump, Tariffs, Currency & CHINA – A Deep Economic Analysis 📉🌎

By @FUNDAFORSTOCKS

🚨 The global economy is shifting rapidly! This thread breaks down the key issues affecting markets today:

✅ Trump’s trade policies & tariffs
✅ Inflation & interest rates
✅ Financial markets vs. real economy
✅ Emerging market struggles
✅ China’s overproduction crisis
A MUST-READ 🧵👇

[Finkarma @finkarmaIN]

📢 Final Thoughts:
The economy is at a tipping point. Tariffs, inflation, currency shifts, & trade wars could lead to major economic disruptions.

Will policymakers act in time? Or are we heading toward a financial crisis? 🤔

What do YOU think? Drop your thoughts below! 👇💬 #Economy #TradeWars #Inflation

[Finkarma @finkarmaIN]

Follow @FUNDAFORSTOCKS
https://t.co/w6TKzJuEAI

[Finkarma @finkarmaIN]

Capex Plans: Big Investments Coming! 💰

💰 Total Investment: ₹9.5B (FY25-27)
🔹 New plants for MEHQ, Guaiacol, Anisole, Iso Amylene, 4-MAP
🔹 Major capacity expansion by Q4FY25

[Finkarma @finkarmaIN]

Follow @finkarmaIN
https://t.co/Wt8VuMg3Ip